Stock ARDS ARIDIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Market Closed - OTC Markets
Other stock markets
 03:30:38 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.0635 USD -1.55% Intraday chart for Aridis Pharmaceuticals, Inc. -9.93% -9.42%
2023 Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
AQ
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
AQ
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K
PU
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer
CI
Aridis Pharmaceuticals Announces $2 Million Offering
AQ
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX
AQ
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index
CI
Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K
PU
Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket
MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index
CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours
MT
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
AQ
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARDS Stock
  4. News Aridis Pharmaceuticals, Inc.